EP4709764A2 - Anticorps monoclonaux humains pour le traitement de sujets souffrant de fibrose pulmonaire - Google Patents

Anticorps monoclonaux humains pour le traitement de sujets souffrant de fibrose pulmonaire

Info

Publication number
EP4709764A2
EP4709764A2 EP24803966.1A EP24803966A EP4709764A2 EP 4709764 A2 EP4709764 A2 EP 4709764A2 EP 24803966 A EP24803966 A EP 24803966A EP 4709764 A2 EP4709764 A2 EP 4709764A2
Authority
EP
European Patent Office
Prior art keywords
seq
antibody
antibodies
chain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24803966.1A
Other languages
German (de)
English (en)
Inventor
Felipe Andrade
Erika DARRAH
Kristen DEMORUELLE
Elizabeth REDENTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP4709764A2 publication Critical patent/EP4709764A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps anti-PAD4 et des compositions contenant lesdits anticorps monoclonaux qui peuvent être utilisés pour traiter une fibrose pulmonaire chez un sujet ayant besoin d'un tel traitement.
EP24803966.1A 2023-05-05 2024-05-02 Anticorps monoclonaux humains pour le traitement de sujets souffrant de fibrose pulmonaire Pending EP4709764A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363464242P 2023-05-05 2023-05-05
PCT/US2024/027419 WO2024233254A2 (fr) 2023-05-05 2024-05-02 Anticorps monoclonaux humains pour le traitement de sujets souffrant de fibrose pulmonaire

Publications (1)

Publication Number Publication Date
EP4709764A2 true EP4709764A2 (fr) 2026-03-18

Family

ID=93430946

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24803966.1A Pending EP4709764A2 (fr) 2023-05-05 2024-05-02 Anticorps monoclonaux humains pour le traitement de sujets souffrant de fibrose pulmonaire

Country Status (2)

Country Link
EP (1) EP4709764A2 (fr)
WO (1) WO2024233254A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952132T3 (es) * 2015-03-06 2023-10-27 Public Univ Corp Yokohama City Univ Nuevo anticuerpo anti-pad4
US11807663B2 (en) * 2018-02-01 2023-11-07 Innovent Biologics (Suzhou) Co., Ltd. Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof
CA3136281C (fr) * 2019-05-30 2024-06-25 Shandong Boan Biotechnology Co., Ltd. Anticorps ou recepteur antigenique chimerique ciblant la claudine 18.2

Also Published As

Publication number Publication date
WO2024233254A2 (fr) 2024-11-14
WO2024233254A3 (fr) 2025-05-01

Similar Documents

Publication Publication Date Title
US20230060847A1 (en) Anti-bcma heavy chain-only antibodies
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
CN110431151B (zh) 仅有重链的抗bcma抗体
ES2774016T3 (es) Anticuerpos anti-cd40 y usos de los mismos
JP2024503724A (ja) 免疫調節抗体およびその使用
EP4709764A2 (fr) Anticorps monoclonaux humains pour le traitement de sujets souffrant de fibrose pulmonaire
WO2024233251A2 (fr) Anticorps monoclonaux humains qui améliorent pad4 pour une utilisation dans des maladies auto-immunes
RU2804456C1 (ru) Связывающие молекулы, специфичные к ил-21, и области их применения
HK40022776A (en) Anti-bcma heavy chain-only antibodies
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR